In the pipeline
Our pipeline is focused on research in therapeutic areas where we can accelerate the development of transformational, life-changing medicines for patients
- X
Our pipeline at a glance
As of April 24, 2025
44
Compounds in development
40+
Disease areas being studied
Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.
In the pipeline
Filter
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Brand Name / Compound
Research Area / Line of Therapy
Phase 1 P 1
Phase 2 P 2
Phase 3 P 3
{"categoryColor":"#595454","phase":[{"name":"1 - Phase I","value":"bms:phase/phase-1","desc":"1"},{"name":"2 - Phase II","value":"bms:phase/phase-2","desc":"2"},{"name":"3 - Phase III","value":"bms:phase/phase-3","desc":"3"}],"listings":[{"compoundname":"<p><b>iza-bren<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors *<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='/content/dam/packageinserts/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L NSCLC PD-L1≥50%<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b><a href='/content/dam/packageinserts/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br />\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjuvant Hepatocellular Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br />\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Peri-adjuvant Muscle-Invasive Urothelial Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/bladder"},{"compoundname":"<p><b>iberdomide<\/b><br />\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>iberdomide<\/b><br />\r\n<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Post-Autologous Stem Cell Transplant Maintenance Newly Diagnosed Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>mezigdomide<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ Multiple Myeloma Vd<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>mezigdomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L+ Multiple Myeloma Kd<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''>REBLOZYL<\/a><\/b><sup>®<\/sup> <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Non-Transfusion Dependent Myelodysplastic Syndrome-Associated Anemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelodysplastic-syndromes"},{"compoundname":"<p><b><a href='http://packageinserts.bms.com/pi/pi_breyanzi.pdf' title='' class='' target='_blank' aria-label=''>BREYANZI<\/a><sup>®<\/sup> (lisocabtagene maraleucel)<\/b><br>\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Relapsed/Refractory Marginal Zone Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦High Risk 1L Large B-cell Lymphoma<\/p>\r\n<p> <\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L+ Follicular Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Relapsed/Refractory Follicular Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''>REBLOZYL<\/a><\/b><sup>®<\/sup> <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Transfusion Dependent Myelofibrosis-Associated Anemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelofibrosis"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Sjögren's Syndrome<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Psoriatic Arthritis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>afimetoran<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>admilparant<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦Idiopathic Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>admilparant<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Progressive Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>IL2-CD25<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>AR LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦Metastatic Castration-Resistant Prostate Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/prostate"},{"compoundname":"<p><b>FAAH/MAGL Dual Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Multiple Sclerosis Spasticity<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>FAAH/MAGL Dual Inhibitor<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Alzheimer's Disease Agitation<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>arlo-cel<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2-4L Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>arlo-cel<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Relapsed/Refractory Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>MYK-224<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Heart Failure with Preserved Ejection Fraction<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>Anti-CCR8<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>Anti-MTBR Tau<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>eIF2B Activator<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>PKCθ Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p><b>✦<\/b>Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>subcutaneous nivolumab + relatlimab + rHuPH20<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L Melanoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/melanoma"},{"compoundname":"<p><b>milvexian<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Acute Coronary Syndrome<b><sup>*<\/sup><\/b><\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>milvexian<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Atrial Fibrillation<sup>*<\/sup><\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>milvexian<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Secondary Stroke Prevention<sup>*<\/sup><\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Severe Refractory Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Autoimmune Diseases<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>obexelimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦IgG4-Related Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BCL6 LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>BMS-986454<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BMS-986460<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Prostate Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/prostate"},{"compoundname":"<p><b>CD33-GSPT1 ADC<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Acute Myeloid Leukemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia"},{"compoundname":"<p><b>Dual Targeting BCMAxGPRC5D CAR T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Relapsed/Refractory Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L Colorectal Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/colorectal"},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Multiple Sclerosis<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Myasthenia Gravis<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>SOS1 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Extensive Stage SCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''>COBENFY<\/a><sup>TM<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Psychosis in Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>TRPC4/5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Mood and Anxiety Disorders<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='' aria-label=''>REBLOZYL<\/a><\/b>® <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>A-Thalassemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/a-thalessemia"},{"compoundname":"<p><b>BMS-986495<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Neurodegenerative Diseases<b><sup>*<\/sup><\/b><\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>WEE1 CELMoD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>HbF Activating CELMoD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Sickle Cell Disease<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/sickle-cell-disease"},{"compoundname":"<p><b>nivolumab+relatlimab HD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L NSCLC PD-L1≥1%<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>BMS-986484<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>RYZ801<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Hepatocellular Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><b>atigotatug + nivolumab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L Extensive Stage SCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>HR+/HER2- Unresectable Metastatic Breast Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/breast"},{"compoundname":"<p><b>iza-bren<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>1L NSCLC *<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>iza-bren<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Metastatic NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>BMS-986490<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>BMS-986488<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>BMS-986482<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>iza-bren<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦ 1L Triple-Negative Breast Cancer<\/p>\r\n","category":"bms:therapeutiic-area/oncology","subcategory":"bms:tumor/breast"}],"therapeuticarea":[{"color":"#dbc5c5","name":"bms:therapeutiic-area/cardiovascular","value":"Cardiovascular"},{"color":"#fedcca","name":"bms:therapeutiic-area/hematology","list":[{"name":"bms:tumor/a-thalessemia","value":"A-Thalessemia"},{"name":"bms:tumor/acute-myeloid-leukemia","value":"Acute Myeloid Leukemia (AML)"},{"name":"bms:tumor/lymphoma","value":"Lymphoma"},{"name":"bms:tumor/multiple-myeloma","value":"Multiple Myeloma (MM)"},{"name":"bms:tumor/myelodysplastic-syndromes","value":"Myelodysplastic Syndromes (MDS)"},{"name":"bms:tumor/myelofibrosis","value":"Myelofibrosis (MF)"},{"name":"bms:tumor/sickle-cell-disease","value":"Sickle Cell Disease"}],"value":"Hematology"},{"color":"#c5ffe6","name":"bms:therapeutiic-area/immunology","value":"Immunology"},{"color":"#d8ddd1","name":"bms:therapeutiic-area/neuroscience","value":"Neuroscience"},{"color":"#c0f2fb","name":"bms:therapeutiic-area/oncology","list":[{"name":"bms:tumor/bladder","value":"Bladder"},{"name":"bms:tumor/breast","value":"Breast"},{"name":"bms:tumor/colorectal","value":"Colorectal"},{"name":"bms:tumor/hepatocellular-carcinoma","value":"Hepatocellular Carcinoma (HCC)"},{"name":"bms:tumor/lung","value":"Lung"},{"name":"bms:tumor/melanoma","value":"Melanoma"},{"name":"bms:tumor/prostate","value":"Prostate"},{"name":"bms:tumor/solid-tumors","value":"Solid Tumors"}],"value":"Oncology"}],"subCategoryColor":"#A69F9F"}
Oncology
Solid Tumors
Anti-CCR8
✦Solid Tumors
BMS-986482
✦Solid Tumors
BMS-986484
✦Solid Tumors
BMS-986488
✦Solid Tumors
BMS-986490
✦Solid Tumors
iza-bren
Solid Tumors *
PRMT5 Inhibitor
Solid Tumors
RYZ101
✦2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors
SOS1 Inhibitor
✦Solid Tumors
WEE1 CELMoD
✦Solid Tumors
Lung
atigotatug + nivolumab
✦1L Extensive Stage SCLC
iza-bren
1L NSCLC *
Metastatic NSCLC
1L NSCLC
nivolumab+relatlimab HD
✦1L NSCLC PD-L1≥1%
PRMT5 Inhibitor
✦NSCLC
RYZ101
Extensive Stage SCLC
Hepatocellular Carcinoma (HCC)
RYZ801
✦Hepatocellular Carcinoma
Bladder
Prostate
AR LDD
✦Metastatic Castration-Resistant Prostate Cancer
BMS-986460
✦Prostate Cancer
Melanoma
subcutaneous nivolumab + relatlimab + rHuPH20
✦1L Melanoma
Colorectal
Breast
iza-bren
✦ 1L Triple-Negative Breast Cancer
RYZ101
HR+/HER2- Unresectable Metastatic Breast Cancer
Hematology
Multiple Myeloma (MM)
arlo-cel
2-4L Multiple Myeloma
✦Relapsed/Refractory Multiple Myeloma
Dual Targeting BCMAxGPRC5D CAR T
✦Relapsed/Refractory Multiple Myeloma
iberdomide
✦2L+ Multiple Myeloma
Post-Autologous Stem Cell Transplant Maintenance Newly Diagnosed Multiple Myeloma
mezigdomide
✦2L+ Multiple Myeloma Vd
2L+ Multiple Myeloma Kd
Myelodysplastic Syndromes (MDS)
REBLOZYL®
(luspatercept-aamt)
1L Non-Transfusion Dependent Myelodysplastic Syndrome-Associated Anemia
Lymphoma
BCL6 LDD
✦Lymphoma
golcadomide
✦High Risk 1L Large B-cell Lymphoma
2L+ Follicular Lymphoma
Relapsed/Refractory Follicular Lymphoma
Myelofibrosis (MF)
Acute Myeloid Leukemia (AML)
CD33-GSPT1 ADC
✦Acute Myeloid Leukemia
A-Thalessemia
Sickle Cell Disease
HbF Activating CELMoD
✦Sickle Cell Disease
Immunology
admilparant
✦Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
afimetoran
✦Systemic Lupus Erythematosus
BMS-986454
✦Autoimmune Disease
CD19 NEX-T
✦Severe Refractory Systemic Lupus Erythematosus
Autoimmune Diseases
IL2-CD25
✦Autoimmune Disease
obexelimab
✦IgG4-Related Disease
PKCθ Inhibitor
✦Autoimmune Disease
Psoriatic Arthritis
Systemic Lupus Erythematosus
Neuroscience
Anti-MTBR Tau
✦Alzheimer's Disease
BMS-986495
✦Neurodegenerative Diseases*
CD19 NEX-T
Multiple Sclerosis
Myasthenia Gravis
eIF2B Activator
✦Alzheimer's Disease
FAAH/MAGL Dual Inhibitor
✦Multiple Sclerosis Spasticity
Alzheimer's Disease Agitation
TRPC4/5 Inhibitor
✦Mood and Anxiety Disorders
Cardiovascular
milvexian
Acute Coronary Syndrome*
Atrial Fibrillation*
Secondary Stroke Prevention*
MYK-224
✦Heart Failure with Preserved Ejection Fraction
Please click on product name to see the Full U.S. Prescribing Information for KRAZATI®, OPDIVO®, REBLOZYL®, BREYANZI®, SOTYKTU™, and COBENFY™ including Boxed WARNINGS for BREYANZI®.
Development Partnership: Anti-CCR8 + nivolumab, nivolumab + relatlimab HD, OPDIVO, YERVOY: Ono; AUGTYRO, COBENFY, KRAZATI: Zai Lab; BMS-986495: Prothena; iza-bren: SystImmune; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; REBLOZYL: Merck; rHuPH20: Halozyme
* Partner-run study
✦ NME Lead Indication
NSCLC = Non-Small Cell Lung Cancer
SCLC = Small Cell Lung Cancer
ADC = Antibody Drug Conjugate
For information on approved uses, refer to approved product labeling. Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.